Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OIF + beta-tricalcium phosphate
- Development stage
- Unknown
- Lead developer
- Novadip Biosciences
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Implant
01
Overview
OIF + beta-tricalcium phosphate is a combination bone graft substitute consisting of a novel recombinant protein, **Osteogenic Induction Factor (OIF)**, and a bioresorbable ceramic scaffold, **beta-tricalcium phosphate (β-TCP)**. Developed by **OsteoPharma**, OIF is a 12 kDa protein that induces the differentiation of mesenchymal stem cells (MSCs) into osteoblasts through a mechanism distinct from the well-known Bone Morphogenetic Proteins (BMPs). The β-TCP component serves as a biocompatible scaffold that supports cell attachment and is gradually replaced by natural bone tissue during the healing process. This combination is primarily being investigated for the treatment of complex bone fractures, distal radius fractures, and bone non-unions, aiming to provide an effective alternative to autologous bone grafting.
- Other names
- OIF/beta-TCPOsteogenic Induction Factor + beta-tricalcium phosphateOsteogenic Induction Factor/beta-TCP
02
Targets
BMPR (Bone morphogenetic protein receptor)
Beyond the preview
Go deeper on OIF + beta-tricalcium phosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OIF + beta-tricalcium phosphate.